Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This investigational cell therapy consists of adipose-derived mesenchymal stem cells (AD-MSCs) being developed by the Guangdong Provincial Hospital of Traditional Chinese Medicine for the treatment of moderate to severe psoriasis vulgaris. AD-MSCs are multipotent adult stem cells isolated from adipose tissue that exhibit significant immunomodulatory and anti-inflammatory properties. In clinical research (NCT03265613), these cells are administered via intravenous infusion, often as part of a combination regimen including topical calcipotriol and the traditional Chinese medicine formula PSORI-CM01. The therapy aims to modulate the immune-mediated inflammatory pathways characteristic of psoriasis pathogenesis by interacting with various immune cells, such as T cells, B cells, and natural killer (NK) cells, to reduce systemic and localized skin inflammation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on adipose-derived mesenchymal stem cells (Guangdong Provincial Hospital of Traditional Chinese Medicine).